HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats.

AbstractAIM:
To determine whether intravitreal injection of tacrolimus suppresses ongoing experimental autoimmune uveoretinitis (EAU) in rats.
METHODS:
Rats were immunised with interphotoreceptor retinoid-binding protein peptide (R14) and given an intravitreal injection of tacrolimus on day 12 after immunisation. Intraocular inflammation was assessed by slit-lamp biomicroscopy and histopathological examination. Interferon gamma and tumour necrosis factor alpha protein levels in the ocular tissues were measured. Gene expression of chemokines was determined in ocular tissues by reverse transcription-polymerase chain reaction. To evaluate the systemic effect of intravitreal injection of tacrolimus, delayed-type hypersensitivity was measured by ear swelling.
RESULTS:
Clinical and pathological scores showed that ocular inflammation of tacrolimus-treated eyes was markedly less than that of vehicle-treated eyes. The amount of interferon gamma and tumour necrosis factor alpha was considerably inhibited in tacrolimus-treated eyes. The gene expression of monocyte chemattractant protein-1 (MCP-1) and regulated upon activation, normal T cell expressed and secreted (RANTES) was markedly reduced in tacrolimus-treated eyes. Delayed-type hypersensitivity responses were not impaired in tacrolimus-treated rats.
CONCLUSIONS:
Intravitreal injection of tacrolimus was highly effective in suppressing the ongoing process of EAU without any side effects on systemic cellular immunity. This treatment may be useful in the management of patients with severe uveitis.
AuthorsKeiko Oh-i, Hiroshi Keino, Hiroshi Goto, Naoyuki Yamakawa, Kouhei Murase, Yoshihiko Usui, Takeshi Kezuka, Jun-Ichi Sakai, Masaru Takeuchi, Masahiko Usui
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 91 Issue 2 Pg. 237-42 (Feb 2007) ISSN: 0007-1161 [Print] England
PMID16987901 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Chemokines
  • Immunosuppressive Agents
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma
  • Tacrolimus
Topics
  • Animals
  • Autoimmune Diseases (drug therapy, immunology, metabolism)
  • Cells, Cultured
  • Chemokines (biosynthesis, genetics)
  • Eye (metabolism)
  • Female
  • Gene Expression Regulation (drug effects)
  • Hypersensitivity, Delayed
  • Immunity, Cellular (drug effects)
  • Immunosuppressive Agents (administration & dosage, adverse effects, therapeutic use)
  • Injections
  • Interferon-gamma (biosynthesis)
  • Macrophages (drug effects, metabolism)
  • RNA, Messenger (genetics)
  • Rats
  • Rats, Inbred Lew
  • Retinitis (drug therapy, immunology, metabolism)
  • Tacrolimus (administration & dosage, therapeutic use, toxicity)
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (biosynthesis)
  • Uveitis (drug therapy, immunology, metabolism)
  • Vitreous Body

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: